The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
ApexOnco Front Page
Recent articles
The company will license EGFR and cMet inhibitors from Celyn.
The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
2026’s first big oncology buyout is here.
But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
Just like other oral SERDs, filing is restricted to the ESR1-mutant population.
Darovasertib data are promised for the last week of March.
The company buys in a PI3Kα and mTOR combo.
